Atossa Therapeutics Inc. [NASDAQ: ATOS] closed the trading session at $2.29 on 11/18/21. The day’s price range saw the stock hit a low of $2.27, while the highest price level was $2.445. The company report on November 15, 2021 that Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update.
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, announces financial results for the fiscal quarter ended September 30, 2021, and provides an update on recent company developments.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Key developments from Q3 2021 and to date include:.
The stocks have a year to date performance of 141.05 percent and weekly performance of -10.89 percent. The stock has been moved at -29.10 percent over the last six months. The stock has performed -21.31 percent around the most recent 30 days and changed -29.75 percent over the most recent 3-months.
If compared to the average trading volume of 4.68M shares, ATOS reached to a volume of 5871242 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Atossa Therapeutics Inc. [ATOS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ATOS shares is $7.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ATOS stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Atossa Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 26, 2018.
The Average True Range (ATR) for Atossa Therapeutics Inc. is set at 0.15 The Price to Book ratio for the last quarter was 1.94, with the Price to Cash per share for the same quarter was set at 1.18.
ATOS stock trade performance evaluation
Atossa Therapeutics Inc. [ATOS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.89. With this latest performance, ATOS shares dropped by -21.31% in over the last four-week period, additionally sinking by -29.10% over the last 6 months – not to mention a rise of 51.66% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATOS stock in for the last two-week period is set at 28.48, with the RSI for the last a single of trading hit 22.37, and the three-weeks RSI is set at 33.07 for Atossa Therapeutics Inc. [ATOS]. The present Moving Average for the last 50 days of trading for this stock 2.99, while it was recorded at 2.49 for the last single week of trading, and 3.38 for the last 200 days.
Atossa Therapeutics Inc. [ATOS]: An insightful look at the core fundamentals
Return on Total Capital for ATOS is now -72.33, given the latest momentum, and Return on Invested Capital for the company is -88.40. Return on Equity for this stock declined to -88.42, with Return on Assets sitting at -62.18. When it comes to the capital structure of this company, Atossa Therapeutics Inc. [ATOS] has a Total Debt to Total Equity ratio set at 0.07. Additionally, ATOS Total Debt to Total Capital is recorded at 0.07, with Total Debt to Total Assets ending up at 0.04.
Reflecting on the efficiency of the workforce at the company, Atossa Therapeutics Inc. [ATOS] managed to generate an average of -$2,228,494 per employee.Atossa Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 81.20 and a Current Ratio set at 81.20.
Earnings per share (EPS) analysis for Atossa Therapeutics Inc. [ATOS] stock
With the latest financial reports released by the company, Atossa Therapeutics Inc. posted -0.34/share EPS, while the average EPS was predicted by analysts to be reported at -0.34/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ATOS.
Atossa Therapeutics Inc. [ATOS]: Insider Ownership positions
There are presently around $71 million, or 32.10% of ATOS stock, in the hands of institutional investors. The top three institutional holders of ATOS stocks are: BLACKROCK INC. with ownership of 9,550,629, which is approximately 6.66% of the company’s market cap and around 0.04% of the total institutional ownership; VANGUARD GROUP INC, holding 7,056,461 shares of the stock with an approximate value of $16.16 million in ATOS stocks shares; and STATE STREET CORP, currently with $4.91 million in ATOS stock with ownership of nearly 5.573% of the company’s market capitalization.
Positions in Atossa Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 50 institutional holders increased their position in Atossa Therapeutics Inc. [NASDAQ:ATOS] by around 6,193,089 shares. Additionally, 40 investors decreased positions by around 10,843,344 shares, while 17 investors held positions by with 14,037,899 shares. The mentioned changes placed institutional holdings at 31,074,332 shares, according to the latest SEC report filing. ATOS stock had 21 new institutional investments in for a total of 2,871,014 shares, while 15 institutional investors sold positions of 3,416,042 shares during the same period.